Results 211 to 220 of about 798,539 (256)
Some of the next articles are maybe not open access.
Clinical issues in antibody design
Trends in Biotechnology, 1995Antibody genes can now be cloned and expressed in various ways to give new versions of antibodies that possess reduced immunogenicity, improved affinity, altered size, increased avidity and novel effector functions. The task for any clinical application is, first, to define a relevant target, and then to design the optimal antibody-based therapeutic ...
K A, Chester, R E, Hawkins
openaire +2 more sources
Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design
Immunology Letters, 2005The variable regions of antibody molecules bind antigens with high affinity and specificity. The binding sites are imparted largely to the hypervariable portions (i.e. CDRs) of the variable region. Peptides derived from antibody CDRs can bind antigen with similar specificity acted as mimic of antibody and become drug-designing core, although with ...
Jiannan, Feng +3 more
openaire +2 more sources
Toward aggregation-resistant antibodies by design
Trends in Biotechnology, 2013Monoclonal antibodies are attractive therapeutics for treating a wide range of human disorders due to their exquisite binding specificity and high binding affinity. However, a limitation of antibodies is their highly variable and difficult-to-predict propensities to aggregate when concentrated during purification and delivery.
Christine C, Lee +2 more
openaire +2 more sources
Molecular Dynamics Methods for Antibody Design
2022Complex and coordinated dynamics are closely connected with protein functions, including the binding of antibodies to antigens. Knowledge of such dynamics could improve the design of antibodies. Molecular dynamics (MD) simulations provide a "computational microscope" that can resolve atomic motions and inform antibody design efforts.
Matthew Carter, Childers +1 more
openaire +2 more sources
Multivalent antibodies: when design surpasses evolution
Trends in Biotechnology, 2010Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer.
Cuesta Martínez, Ángel +4 more
openaire +3 more sources
Potent antibody therapeutics by design
Nature Reviews Immunology, 2006Antibodies constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.
openaire +2 more sources
Design of synthetic antibody libraries
Expert Opinion on Biological Therapy, 2007Antibody libraries came into existence 15 years ago when the accumulating sequence data of immunoglobulin genes and the advent of polymerase chain reaction technology made it possible to clone antibody gene repertoires. Since then, virtually hundreds of antibody libraries have been constructed, employing limitless maneuvers from the antibody ...
openaire +2 more sources
Antibody design: Beyond the natural limits
Trends in Biotechnology, 1994Dissection of antibody-antigen interactions requires a knowledge of antibody structure, the ability to model accurately the conformation of antibody-combining sites, and an understanding of the energetic factors governing the interactions. When this understanding has reached the point where the molecular shape and chemical character of a combining site
A R, Rees +5 more
openaire +2 more sources
Therapeutic antibodies: Discovery, design and deployment
Molecular Immunology, 2015Therapeutic antibodies have come of age with major progress being made in cancer, autoimmunity and chronic inflammation, as well as a wide range of other human diseases. Antibody engineering is further driving development of novel antibody formats and genetically modified cell-based therapies that harness the power of the immune system to progress ...
Ramsland, Paul +2 more
openaire +3 more sources
Rational Design of Antibody Protease Inhibitors
Journal of the American Chemical Society, 2015The bovine antibody BLV1H12, which has an ultralong CDR3H, provides a novel scaffold for engineering new functions into the antibody's variable region. By modifying the β-strand "stalk" of BLV1H12 with sequences derived from natural or synthetic protease inhibitors, we have generated antibodies that inhibit bovine trypsin and human neutrophil elastase (
Tao, Liu +7 more
openaire +2 more sources